GP2

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Retrieved on: 
Tuesday, March 12, 2024
Principal, GP2, Faculty, Breast cancer, Gregorio, Immunotherapy, Disease, Patient, Knowledge, GM-CSF, Research, Hospital, Observation, Pi, Cancer, Death, Teaching hospital, Baylor College of Medicine, ECIS, Complutense University of Madrid, Woman, Prognosis, Book, Vaccine, Map

The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.

Key Points: 
  • The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
  • These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week.
  • Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
  • Breast cancer is the leading cause of death in women between the ages 35-45 in Spain with 6,836 deaths in 2022.

O3 Mining Drill Results Confirm VMS Deposit Environment at Horizon Project

Retrieved on: 
Monday, November 13, 2023
Anomaly, OIII, IP, Gold, Copper, Magnetic anomaly, Breakwater Resources, Horizon Project, VMS, Zinc, Val-d'Or, Cauldron, Lead, Silver, Noranda, Sedimentary exhalative deposits, Cauldon, Horizon, Matagami, Government, Rare-earth element, Communications satellite, Abitibi, GP2

TORONTO, Nov. 13, 2023 /PRNewswire/ - O3 Mining Inc. (TSXV: OIII) (OTCQX: OIIIF) ("O3 Mining" or the "Corporation") is pleased to announce that it has received the results of the two inaugural drill holes completed over the prospective Volcanogenic Massive Sulphide ("VMS") belt within the Horizon Project, in Val-d'Or, Québec, Canada ("Horizon" or the "Horizon Project").

Key Points: 
  • TORONTO, Nov. 13, 2023 /PRNewswire/ - O3 Mining Inc. (TSXV: OIII) (OTCQX: OIIIF) ("O3 Mining" or the "Corporation") is pleased to announce that it has received the results of the two inaugural drill holes completed over the prospective Volcanogenic Massive Sulphide ("VMS") belt within the Horizon Project, in Val-d'Or, Québec, Canada ("Horizon" or the "Horizon Project").
  • O3 Mining's President and Chief Executive Officer, Mr. José Vizquerra commented: "We are very excited about the initial results at the Horizon Project that confirm the discovery of a fertile environment supporting a highly prospective VMS deposit.
  • The sizeable prospective belt within the Horizon Project and the multiple geophysical anomalies identified by O3 Mining have provided the fundamental elements that allow for the discovery of VMS deposits.
  • The next steps at the Horizon Project will consist of fence drilling to identify the prospective horizons in terms of VMS deposition or emplacement.

Verily launches Viewpoint Workbench to unify data and accelerate biomedical research

Retrieved on: 
Thursday, October 5, 2023
Research, Networks, Pharmaceutical, Data Management, Technology, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Parkinson's disease, ALS, The Michael J. Fox Foundation, Biomedical Research, Drug development, GP2, Organization, Data, Disease, AMP, Collection, Ecosystem, Environment, MJFF, Policy, Bangladesh Technical Education Board, Drug discovery, Genomics, ASAP, Medical device, Pharmaceutical industry, Helix, Workbench, M.B.B.S

Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.

Key Points: 
  • Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.
  • Workbench provides a secure collaborative environment for data generators, research, and biopharma organizations to govern and analyze their data.
  • Data generating organizations, research sponsors, and biomedical researchers can use Workbench to securely connect with stakeholders and partners, explore and analyze multimodal data, and simplify data governance with access control and policy enforcement.
  • Workbench users can tap into a growing ecosystem of data sources and researchers, to build on collective scientific progress, share best practices, and conduct reproducible research.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Study of Parkinson's Disease Genetics in Black and African American Populations Expands with Two Additional Sites

Retrieved on: 
Monday, February 27, 2023
Parkinson's disease, DSM-IV codes, Florida College, GP2, Kaiser Permanente, University of Florida, Volunteering, DNA, University of Chicago, Louisiana State University, University, Rush University, PD, MJFF, University of Florida College of Medicine-Jacksonville, Research, Disease, Partnership, Genetics, ASAP, The Michael J. Fox Foundation, Science, Genetic programming, Shock, University of Alabama, African Americans, MS, Pharmaceutical industry, Nursing, MD, Black

"The BLAAC PD study is an opportunity for Black and African American people to participate in the pursuit of cures for Parkinson's — the fastest growing neurological disease — for themselves, their children and their community.

Key Points: 
  • "The BLAAC PD study is an opportunity for Black and African American people to participate in the pursuit of cures for Parkinson's — the fastest growing neurological disease — for themselves, their children and their community.
  • The study is recruiting volunteers from the Black or African American community — people with Parkinson's disease and people without the disease or a family history of Parkinson's (control participants).
  • "We are grateful to the participant and clinical site partners building this study to learn more about Parkinson's-linked genetic changes in Black and African American populations toward better treatments for all."
  • Fox Foundation supports additional efforts — some feeding to GP2 — to explore population-specific genetics, clinical disease experience, and access to care.

Greenwich LifeSciences Provides Year End Update

Retrieved on: 
Thursday, December 29, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, David Geffen School of Medicine at UCLA, Baylor College of Medicine, Baylor University Medical Center, Texas Oncology, Department of Medicine – University of Pamplona, Grey Literature International Steering Committee, Dan, Woman, Immunotherapy, Patient, Northwestern University, Baylor University, Committee, Santa Claus, UCLA, HER2, Feinberg School of Medicine, Hematology, GP2, Management, Medical imaging, Pharmaceutical industry, McKesson Corporation, Medicine, Breast cancer

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.
  • We believe that GP2 carries great potential to improve outcomes for patients with HER2 positive breast cancer.
  • The Company has added a new page to its website to provide updates to Flamingo-01 which includes a map of participating clinical sites in the US (view here ).
  • The current listing of US sites from www.clinicaltrials.gov with email contact information for some sites is also shown below and will be continually updated during the trial:

FRED VASSEUR APPOINTED SCUDERIA FERRARI TEAM PRINCIPAL  

Retrieved on: 
Tuesday, December 13, 2022
2010 GP2 Series, NYSE, Ferrari, Scuderia Ferrari, Formula One, Nico Rosberg, Tifosi, GP2, Vasseur, History, Sauber Motorsport, Management, Scuderia, Maranello

Maranello (Italy), December 13, 2022 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) today announced that Fred Vasseur will join Scuderia Ferrari on 9 January as Team Principal and General Manager.

Key Points: 
  • Maranello (Italy), December 13, 2022 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) today announced that Fred Vasseur will join Scuderia Ferrari on 9 January as Team Principal and General Manager.
  • Vasseur has most recently held the position of CEO and Team Principal of Sauber Motorsport (currently Alfa Romeo F1 Team) since 2017.
  • Commenting on the appointment, Ferrari CEO Benedetto Vigna said: “We are delighted to welcome Fred Vasseur to Ferrari as our Team Principal.
  • This approach and his leadership are what we need to push Ferrari forward with renewed energy.”
    Fred Vasseur commented: “I am truly delighted and honoured to take over the leadership of Scuderia Ferrari as Team Principal.

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Retrieved on: 
Thursday, December 1, 2022
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Recurrence, Breast, HER2/neu, GM-CSF, DTH, HLA, Cancer, Patient, Phase, IPO, Survivor, Trastuzumab, Security (finance), Baylor College of Medicine, MD Anderson Cancer Center, Breast cancer, Woman, Immunotherapy, Safety, Pharmaceutical industry, GP2

During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.

Key Points: 
  • During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .
  • Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Retrieved on: 
Thursday, August 11, 2022
Research, Pharmaceutical, Oncology, Other Education, Other Manufacturing, Education, Packaging, Clinical Trials, Science, Surgery, Manufacturing, Health, Woman, Baylor College of Medicine, U.S. Securities and Exchange Commission, Phase, Survival, Forward-looking statement, Recurrence, MD Anderson Cancer Center, Population, Security (finance), Cancer, HLA, Patient, Company, Twitter, Acquisition, Breast cancer, Trastuzumab, Safety, Reproduction, Breast, Survivor, Immunotherapy, HER2/neu, Nasdaq, DTH, Pharmaceutical industry, Vaccine, GP2

The trial will be led by Baylor College of Medicine and will include US and international clinical sites from university-based hospitals and cooperative networks.

Key Points: 
  • The trial will be led by Baylor College of Medicine and will include US and international clinical sites from university-based hospitals and cooperative networks.
  • The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on GP2 immune response and clinical data, please visit the Companys clinical trial tab at https://greenwichlifesciences.com/clinical-trials/ .